Sleep apnea in young abstinent recreational MDMA (“ecstasy”) consumers

Una D. McCann, MD
Francis P. Sgambati, BSE
Alan R. Schwartz, MD
George A. Ricaurte, MD,
PhD

Address correspondence and
reprint requests to Dr. Una D.
McCann, Department of
Psychiatry, The Johns Hopkins
School of Medicine, 5501
Hopkins Bayview Circle, Room
5B71c, Baltimore, MD 21224
umccann@jhmi.edu

ABSTRACT

Background: Methylenedioxymethamphetamine (MDMA, “ecstasy”) is a popular recreational drug of abuse and a selective brain serotonin neurotoxin. Functional consequences of MDMA neurotoxicity have defied ready characterization. Obstructive sleep apnea (OSA) is a common form of sleep-disordered breathing in which brain serotonin dysfunction may play a role. The present study sought to determine whether abstinent recreational MDMA users have an increased prevalence of OSA.

Methods: We studied 71 medically healthy recreational MDMA users and 62 control subjects using all-night sleep polysomnography in a controlled inpatient research setting. Rates of apneas, hypopneas, and apnea hypopnea indices were compared in the 2 groups, controlling for body mass index, age, race, and gender.

Results: Recreational MDMA users who had been drug free for at least 2 weeks had significantly increased rates of obstructive sleep apnea and hypopnea compared with controls. The odds ratio (95% confidence interval) for sleep apnea (mild, moderate, and severe combined) in MDMA users during non-REM sleep was 8.5 (2.4–30.4), which was greater than that associated with obesity [6.9 (1.7–28.2)]. Severity of OSA was significantly related to lifetime MDMA exposure.

Conclusions: These findings suggest that prior recreational methylenedioxymethamphetamine use increases the risk for obstructive sleep apnea and lend support to the notion that brain serotonin neuronal dysfunction plays a role in the pathophysiology of sleep apnea. *Neurology*® 2009; 73:2011–2017

GLOSSARY

AHI = apnea hypopnea index; **BMI** = body mass index; **DSM-IV** = *Diagnostic and Statistical Manual of Mental Disorders*, 4th edition; **MDMA** = methylenedioxymethamphetamine; **NREM** = non-REM; **OR** = odds ratio; **OSA** = obstructive sleep apnea; **PSG** = polysomnography; **SCID-I** = Scheduled Diagnostic Interview for *DSM-IV*; **SDB** = sleep-disordered breathing.

Obstructive sleep apnea (OSA) is a highly prevalent sleep disorder that is estimated to afflict approximately 15 million adult Americans¹ and is characterized by repeated episodes of apnea or hypopnea during sleep. The pathophysiology of sleep apnea is incompletely understood. However, the consequences of OSA can be serious and include daytime sleepiness, cognitive dysfunction, metabolic syndrome, and cardiovascular disease.² Recently, OSA has also been identified as an independent risk factor for death related to cardiovascular causes.^{3,4}

The neurobiologic underpinnings of OSA are not fully understood. However, there has been increased interest in the role of central serotonin systems in its pathogenesis. Brain serotonin neurons modulate sleep and breathing patterns through a variety of different mechanisms. For example, serotonin neurons influence circadian changes in sleep propensity,⁵ mediate cortical arousal,⁶ act as carbon dioxide chemoreceptors that modulate respiratory drive,⁷ and innervate muscles that maintain pharyngeal patency.^{8–11} In addition, there is serotonin neuroanatomical input to the respiratory rhythm generator in the brainstem pre-Bötzinger complex, as well as to spinal respiratory motor neurons.^{12,13} Therefore, although the pathophysiology of sleep

Editorial, page 1947

Supplemental data at
www.neurology.org

e-Pub ahead of print on December 2, 2009, at www.neurology.org.

From the Department of Psychiatry (U.D.M., F.P.S.), Department of Medicine, Division of Pulmonary and Critical Care (A.R.S.), and Department of Neurology (G.A.R.), The Johns Hopkins School of Medicine, Baltimore, MD.

Supported by Public Health Service grants DA16563 (McCann), DA05938 and DA01796401 (Ricaurte), and NCRR grant M01RR002719 (Ford).

Disclosure: Author disclosures are provided at the end of the article.

apnea is complex and may involve a variety of mechanisms,¹⁴ there is reason to believe that altered brain serotonin neuronal function may be involved.

Methylenedioxymethamphetamine (MDMA, “ecstasy”) is a popular recreational drug of abuse and a potent selective brain serotonin neurotoxin.^{15,16} Studies in animals, including nonhuman primates, have demonstrated that MDMA leads to lasting dose-related and protracted reductions in a variety of brain serotonin axonal markers, and neuroanatomical studies with immunochemical markers suggest that losses of axonal markers are secondary to a distal axotomy of serotonin neurons.^{17,18} PET imaging studies using radioligands that bind to serotonin transporters provide evidence that MDMA is also neurotoxic in humans.¹⁹⁻²¹ Although functional consequences of MDMA-induced brain serotonin neurotoxicity are not well understood, available data suggest that abstinent MDMA users have alterations in sleep architecture²² and cognitive function.²³⁻²⁶

The present study was conducted in abstinent, otherwise healthy MDMA users whose use characteristics have previously been shown to lead to persistent losses of brain serotonin transporters suggestive of serotonin neurotoxicity. In particular, MDMA users with similar use patterns in studies with identical inclusion criteria have previously been found to have a reduction in brain serotonin transporters as measured by PET.¹⁹ The purpose of this study was to determine whether abstinent MDMA users showed evidence of sleep-disordered breathing (SDB).

METHODS Subjects. All participants (n = 71 MDMA users; n = 62 controls) were medically healthy individuals who responded to recruitment materials posted in newspapers and fliers looking for “club drug users.” The same recruitment materials were used for both MDMA users and controls, and potential subjects were not aware that we were specifically interested in the effects of MDMA. Inclusion in the MDMA subject group required a self-report of 25 or more separate lifetime uses of MDMA because such subjects have previously been shown to have lasting reductions in brain serotonin axonal markers.^{19,27} Inclusion in the control group required that subjects had never used MDMA. Inclusion criteria for all subjects included willingness to abstain from illicit substance use for 2 weeks before study participation, normal results on all medical screening measures (see below), and negative drug screens (with the exception of marijuana, which can remain positive for at least 3 weeks). Exclusion criteria included regular use of prescribed psychotropic

medications, previous diagnosis of a sleep disorder, major medical illness, drug or alcohol dependence, history of significant head injury, and presence of an Axis I psychiatric diagnosis in which serotonin has been implicated (major depression, bipolar affective disorder, obsessive compulsive disorder, panic disorder, psychosis).

To determine whether interested individuals would be included in the study, potential subjects first underwent an initial institutional review board–approved scripted phone screen. Questions in the script were designed to determine whether subjects met inclusion and exclusion criteria. All subjects who met study criteria in the phone screen (for either the MDMA or the control group) were then invited for face-to-face screening. At the time of the face-to-face screen, subjects provided informed written consent before undergoing further evaluation. In addition to drug testing, additional screening measures included routine blood chemistries, HIV screening, complete blood counts, and urine testing for drugs of abuse, including cannabinoids, opiates, cocaine metabolites, alcohol, and amphetamines. If, after laboratory and medical examination, individuals continued to meet full inclusion criteria, they were immediately enrolled and admitted. Notably, before coming for face-to-face screening, subjects had been informed that they needed to abstain from all illicit drug use for 2 weeks, from any alcohol consumption for at least 3 days, that they would be screened for illicit drug use at the time of the screening, and that would be excluded from participation if drug or alcohol screens were positive. All subjects were also interviewed using the Scheduled Diagnostic Interview for *DSM-IV* (SCID-I).²⁸ MDMA (and other drug) use was assessed during the initial phone screen and by a standardized drug questionnaire, nursing assessment upon admission to the inpatient Clinical Research Unit, the SCID-I, and an MDMA-specific questionnaire. If subjects provided inconsistent information, they were excluded from study participation.

Standard protocol approvals, registrations, and patient consents. The research described in this article was approved by an institutional investigational review board. All subjects provided informed, written consent to participate in the research.

Polysomnography. The research took place in a federally funded inpatient clinical research unit. While on the clinical research unit, the sleep schedule was regulated, with a “lights-out” time of 11:00 PM and a “lights-on” time of 7:00 AM. Participants were not permitted to sleep before lights-out time or sleep past lights-on time. The overnight polysomnography (PSG) consisted of continuous recordings of right and left electrooculographic leads, 4 electroencephalographic leads (C3–A3, C4–A1, O1–A2, O2–A1), submental electromyogram, and bilateral anterior tibialis. The electrooculograms and EEGs were recorded at a minimum of 100 Hz and up to 500 Hz, and EMGs were recorded at 200 Hz. Respiration of the participant was monitored by a nasal pressure cannula at the nostrils, a thermistor/thermocouple at the nose and mouth, and thoracic and abdominal strain gauges. Continuous recording of the participant’s oxyhemoglobin saturation was obtained by an oximeter. Scoring of the overnight PSG was visually scored by certified polysomnographers from the Johns Hopkins Sleep Disorders Center, following American Academy of Sleep Medicine Guidelines.²⁹ Apnea and hypopnea measures were characterized as obstructive, central, or mixed. Polysomnographers who scored sleep records were blind to subjects’ group designation (i.e., MDMA vs control). The apnea hypopnea index (AHI) was defined as the mean number of apneas plus hypopneas per hour of sleep, the apnea index was defined as the mean number of apneas

per hour, and the hypopnea index was defined as the mean number of hypopneas per hour. Severity of OSA was defined using conventional definitions (AHI <5 = normal; AHI 5–14 = mild OSA; AHI 15–29 = moderate OSA; AHI ≥30 = severe OSA).

Statistical analysis. Between-group comparisons were performed using a multiple linear regression model comparing disordered breathing rates in MDMA users and control subjects. Stepwise variable selection was used to identify potential significant covariates, including known risk factors for SDB: body mass index (BMI), sex, race, and age. In addition, given the larger number of males in the MDMA group and known gender differences in the prevalence of SDB, we also conducted an analysis comparing SDB measures in males only (see supplemental data on the *Neurology*[®] Web site at www.neurology.org). The significance level used for determining the entry and removal of the covariates from the model was a *p* value ≤0.15. The variable remained in the model only if it retained a *p* value ≥0.10. A multiple logistic regression model was also used to determine the odds ratio (OR) for mild, moderate, and severe obstructive sleep apnea (combined) in MDMA users. Binary variables were created using the AHI during total sleep, during non-REM (NREM) sleep, and during REM sleep. The latent variable was defined as 1 if the AHI was greater than 5 events per hour and 0 otherwise. For the purpose of the logistic regression, age was studied as a continuous variable, whereas BMI was categorized into underweight (BMI <18.5), normal (18.5 ≤ BMI < 25), overweight, (25 ≤ BMI < 30), and obese (30 ≤ BMI < 40).

To assess the potential association between the total number of lifetime MDMA exposures and disordered breathing measures in the MDMA population, Pearson partial correlation coefficients were determined. In these analyses, an individual MDMA exposure was defined as MDMA use in a single setting (e.g., a dance party) and sometimes involved multiple doses over several hours. The same stepwise selection process as described above was used to identify covariates. A similar procedure was conducted to explore the potential relationship between prior cocaine use and SDB, because cocaine has the potential to produce microvascular brain injury that could potentially influence our findings. Statistics were conducted using MATLAB (The Mathworks, Inc., Natick, MA) and SAS (SAS Institute Inc., Cary, NC).

RESULTS Demographics and recreational drug use characteristics of subjects are provided in table 1. The 2 groups did not significantly differ with regard to age or BMI. The proportion of male subjects was higher in the MDMA group, and the proportion of African Americans was higher in the control group. MDMA users, as a group, used more recreational drugs in the past than control subjects.

MDMA users had greater numbers and rates of apneas and hypopneas when compared with controls (table 2 and figure 1), with 80% of the apneas in MDMA users identified as being of the obstructive type, 14% being of the mixed type, and the remaining 6% being of the central type. When data were analyzed using conventional definitions of OSA severity, rates of mild OSA (AHI 5–14) were similar in the 2 groups, but moderate (AHI 15–29) and severe (AHI ≥30) OSA were only observed in the MDMA

Table 1 Demographics of MDMA and control subject groups*

	MDMA (n = 71)	Control (n = 62)
Gender, n[§]		
Male	47	35
Female	24	27
Age, y	23.2 (18–44)	24.1 (18–46)
Race[¶]		
White	41	16
African American	23	44
Hispanic	7	2
BMI, kg/m²	24.9 (17.5–39.1)	26.5 (18.9–29.3)
Total MDMA exposures	192 (30–2,000)	NA
Other drug exposure[†]		
Marijuana[‡]		
Lifetime	69 (97)	38 (61)
Past 6 mo	53 (75)	22 (35)
Hallucinogens[‡]		
Lifetime	57 (80)	6 (10)
Past 6 mo	21 (30)	1 (2)
Cocaine[‡]		
Lifetime	42 (59)	4 (6)
Past 6 mo	24 (34)	2 (3)
Opioids[‡]		
Lifetime	30 (42)	3 (3)
Past 6 mo	11 (15)	1 (2)
Tobacco (current)[‡]		
Past 6 mo	41 (58)	19 (31)

*Categorical values are expressed as whole numbers. Other variables are expressed as mean (range).

†Values represent absolute number (%) of subjects in each group who have ever used a substance in their lifetime and number of subjects who have used the substance within the past 6 months.

‡Numbers represent absolute number of individuals in each group who identified themselves as “smokers” at the time of study participation.

§*p* = 0.02; ¶*p* < 0.01; ||*p* < 0.005. Comparisons were made using a Fisher exact test.

MDMA = methylenedioxymethamphetamine; BMI = body mass index; NA = not applicable.

group (figure 1). Of the 24 MDMA subjects who met criteria for OSA, 22 were aged 31 years or younger. A Fisher exact test (1-tailed) revealed that differences in the rate of moderate and severe sleep apnea observed in the 2 groups were not secondary to chance (*p* = 0.001; table e-1).

Logistic regression during REM, NREM, and total sleep revealed that MDMA users were at increased risk for meeting criteria for sleep apnea (mild, moderate, and severe combined), particularly during

Table 2 Disordered breathing measures in MDMA users and controls

Disordered breathing measure	MDMA (n = 71)	Control (n = 62)	p Value
Total apneas and hypopneas	38.25 (46.28)	22.39 (16.83)	0.003
NREM apneas and hypopneas	25.96 (36.36)	13.23 (12.35)	0.004
REM apneas and hypopneas	12.96 (15.00)	9.16 (8.33)	0.06
AHI	5.57 (6.98)	3.18 (2.34)	0.003
NREM AHI	4.86 (6.86)	2.36 (2.08)	0.003
REM AHI	7.72 (9.71)	6.47 (6.43)	0.13
AI	1.52 (2.77)	0.56 (0.61)	0.02
NREM AI	1.32 (3.02)	0.42 (0.54)	0.04
REM AI	2.00 (3.44)	1.14 (1.94)	0.02
HI	4.11 (5.35)	2.61 (2.08)	0.01
NREM HI	3.59 (5.15)	1.94 (1.85)	0.01
REM HI	5.80 (7.93)	5.33 (5.77)	0.33

Values are mean (SD). *p* Values are derived from a stepwise linear regression procedure described under Methods.

MDMA = methylenedioxymethamphetamine; NREM = non-REM; AHI = apnea hypopnea index; AI = apnea index; HI = hypopnea index.

NREM sleep (table 3). During NREM sleep, MDMA users had more than 8 times the odds of apnea and hypopnea episodes than controls. When only male subjects were considered, the OR for SDB during NREM sleep increased to 11 (table e-2). Prior MDMA use increased the odds for sleep apnea during NREM sleep to a greater degree than BMI in this study population.

Greater lifetime MDMA use was associated with increased rates of sleep apnea ($r = 0.44$, $p = 0.001$; figure 2). Partial correlations between lifetime

MDMA use and sleep apnea and hypopnea indices (controlling for age, gender, BMI, and race) demonstrated a significant relationship between these measures and prior MDMA exposure (table e-3). Prior use of cocaine was not found to be associated with SDB.

DISCUSSION The present study indicates that prior use of the recreational drug and brain serotonin neurotoxin, MDMA, is a risk factor for sleep apnea in otherwise healthy young adults, independent of age, male gender, race, and obesity. Further, the relationship between MDMA use and sleep apnea seems to be directly related to extent of prior MDMA exposure, with greater lifetime MDMA use associated with increased rates of sleep apnea. These findings lend support to the view that brain serotonin systems play a role in the pathophysiology of OSA^{8,10-13} and suggest that sleep apnea is a potential functional consequence of recreational MDMA use.

Although the present findings further implicate brain serotonin dysfunction in sleep apnea and hypopnea, the precise mechanisms involved are not clear. Increased rates of apnea and hypopnea in abstinent recreational MDMA consumers could be related to loss of airway patency due to altered serotonergic input to the hypoglossal motor nucleus.⁸⁻¹¹ Alternatively, sleep apnea in these young individuals could result from faulty chemoreception by serotonergic neurons,⁷ disruption of the respiratory rhythm generator,¹² or defective serotonergic modulation of respiratory motoneurons.¹³ Preclinical models of MDMA-induced serotonin neurotoxicity may also be useful in clarifying these important issues.

Functional consequences of MDMA-induced neurotoxicity in human recreational users have been difficult to identify. The most consistent behavioral differences that have been reported in abstinent MDMA users have been subtle cognitive deficits,²³⁻²⁶ behavioral impulsivity,^{30,31} altered sleep architecture,³⁰ and altered neuroendocrine function.^{32,33} The present study provides evidence that MDMA exposure increases the risk for obstructive sleep apnea, with rates of sleep apnea and hypopnea being directly related to prior MDMA exposure. As discussed below, there may be a relationship among OSA and cognitive deficits and impulsivity in abstinent MDMA users, but it remains to be clarified.

Apneas and hypopneas, by disrupting sleep, may contribute to cognitive deficits found in MDMA users.²²⁻²⁶ This possibility is raised by the fact that chronic sleep disruption is known to have a deleterious effect on daytime cognitive functioning.³⁴ Thus, arousals during sleep secondary to nocturnal hypopneas and apneas could play a role in subtle changes in

Figure 1 Apnea hypopnea indices in abstinent MDMA users and controls

Blue diamonds represent apnea hypopnea index values for subjects in methylenedioxymethamphetamine (MDMA) and control groups. OSA = obstructive sleep apnea.

Table 3 Multiple logistic regression model identifying risk factors for sleep apnea

	NREM and REM		NREM only		REM only	
	OR (95% CI)	p Value	OR (95% CI)	p Value	OR (95% CI)	p Value
MDMA	3.7 (1.4–10.1)	0.01	8.5 (2.4–30.4)	0.001	0.9 (0.4–2.0)	0.82
BMI <18.5	0.5 (0.1–5.3)	0.60	0.7 (0.1–6.8)	0.74	0.7 (0.1–4.1)	0.67
25 ≤ BMI < 30	2.0 (0.7–5.8)	0.21	2.1 (0.6–7.0)	0.24	0.6 (0.2–1.5)	0.26
BMI ≥30	13.5 (3.9–46.9)	<0.0001	6.9 (1.7–28.2)	0.01	3.2 (1.2–8.7)	0.03
Sex	3.3 (1.2–9.7)	0.03	3.2 (0.9–10.8)	0.06	1.9 (0.8–4.4)	0.13
Age	1.1 (1.0–1.2)	0.10	1.2 (1.0–1.3)	0.01	1.1 (1.0–1.2)	0.01

Model adjusted for body mass index (BMI, kg/m²), age, and gender. Normal BMI was used as the reference. Race did not meet criteria to be entered in the model using stepwise regression. NREM = non-REM; OR = odds ratio; CI = confidence interval; MDMA = methylenedioxymethamphetamine.

cognitive function that have been reported in abstinent MDMA users. However, none of the previous polysomnographic studies in MDMA users³⁰ have found significant decreases in sleep latency in MDMA users, suggesting that excessive daytime sleepiness is not the way in which SDB leads to cognitive deficits in abstinent MDMA users. Notably, another aspect of cognitive function that has been found to be altered in MDMA users is impulse control.^{30,31} There is a substantial body of literature indicating that sleep loss in adolescents increases impulsive and risk-taking behavior.^{35,36} Although intriguing, it remains to be determined whether sleep loss is responsible for behavioral findings in MDMA users and, further, whether serotonin neurotoxicity underlies sleep abnormalities and impulsive tendencies in the same individuals.

Figure 2 Apnea hypopnea index vs total lifetime MDMA use

AHI = apnea hypopnea index; MDMA = methylenedioxymethamphetamine.

Limitations of the present study should be acknowledged and include the fact that MDMA users, as a rule, experiment with multiple substances, most commonly marijuana. In theory, one or several of these other substances could play a role in the increased incidence of sleep apneas and hypopneas found in the present group of MDMA users. However, although many drug classes have the potential to influence breathing and respiratory patterns acutely, there are no data suggesting that any of the recreational drugs used by these subjects has long-lasting effects on respiratory function or serotonin neurons. Although some subjects did test positive for marijuana, marijuana use has not been identified as a risk factor for sleep apnea, and exclusion of these subjects did not influence the study outcome. Indeed, cannabinoids have been proposed as a potential treatment for obstructive sleep apnea.³⁷ Cocaine, which has the potential to produce microvascular brain injury, was not associated with SDB in the present study. Another limitation of this study is that drug use reports were retrospective, and self-reported prior drug use is subject to error. However, we have previously found reductions of brain serotonin transporters, as measured by PET, to be significantly associated with self-reported lifetime MDMA exposure.¹⁹ Finally, concerns regarding the role of other drugs of abuse in the present findings are mitigated by the relationship between extent of prior MDMA exposure and sleep apnea and hypopnea in the current study, the known dose-related neurotoxic effects of MDMA toward brain serotonin neurons,^{15–18} and the fact that serotonin has been previously implicated in OSA.⁸

Additional research will be necessary to determine whether sleep abnormalities in MDMA users play a role in subtle cognitive deficits and impulsivity that have previously been identified in this population. Studies that evaluate the relationship between brain serotonin markers and measures of SDB will strengthen conclusions regarding the role of serotonin neurotoxicity in sleep apnea in MDMA users. Preclinical and clinical studies coupling respiratory physiology methodology with functional neuroimaging approaches may be required to determine the neurobiological basis for our findings.

AUTHOR CONTRIBUTIONS

Statistical analyses were performed by Francis P. Sgambati, BSE, and reviewed by Nae-Yuh Wang, PhD (Interdisciplinary Center for Translational Research Biostatistician).

ACKNOWLEDGMENT

The authors thank Dr. Nae-Yuh Wang for his biostatistical review of this manuscript; Emily Dotter, Kristen Kelley, Michael Wilson, and Michael Palermo for research assistance; and the CRU/ICTR nursing staff for their participation in the execution of these studies.

DISCLOSURE

Dr. McCann has served on a scientific advisory board and speakers' bureau for Jazz Pharmaceuticals; has received honoraria from the Public Health Service and the Veterans Administration (grant reviews); and receives research support from the NIH [NIDA R01 DA010217 (PI), NIDA R01 DA16563 (PI), NIDA R01 DA017231-01 A1 (Coinvestigator), NIDA 2 R01 DA05707 (Coinvestigator), NIDA 2 R01 DA05938 (Coinvestigator), and NICHD 1 R01 HD050202-01 (Coinvestigator)]. Mr. Sgambati reports no disclosures. Dr. Schwartz may accrue revenue on US Patent 6457472 (Issued: October 1, 2002): Transtracheal insufflation for treatment of obstructive sleep apnea; serves as a scientific advisor to Apnex, Scientific Advisor, and Cardiac Concepts; and receives research support from the NIH [HL50381 (PI), SCCOR program (Coinvestigator), HL37379 (Coinvestigator), and NCRR (Sleep Core Director, ICTR and Clinical Research Unit)]. Dr. Ricaurte receives research support from the NIH [NIDA K05 DA01796401 (PI), NIDA 5 R01 DA05938 (PI), and NICHD 1 R01 HD050202-01 (PI)].

Received March 12, 2009. Accepted in final form August 12, 2009.

REFERENCES

1. Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing in collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). *Circulation* 2008;118:1080–1111.
2. Pack AI. Advances in sleep-disordered breathing. *Am J Respir Crit Care Med* 2006;173:7–15.
3. Young T, Finn L, Peppard PE, et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. *Sleep* 2008;31:1071–1078.
4. Marshall NS, Wong KK, Liu PY, Cullen SR, Knuiman MW, Grunstein RR. Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study. *Sleep* 2008;31:1079–1085.
5. Challet E. Minireview: entrainment of the suprachiasmatic clockwork in diurnal and nocturnal mammals. *Endocrinology* 2007;148:5648–5655.
6. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. *Nature* 2005;437:1257–1263.
7. Richerson GB. Serotonergic neurons as carbon dioxide sensors that maintain pH homeostasis. *Nat Rev Neurosci* 2004;5:449–461.
8. Veasey SC. Serotonin agonists and antagonists in obstructive sleep apnea: therapeutic potential. *Am J Respir Med* 2003;2:21–29.
9. Volgin DV, Fay R, Kubin L. Postnatal development of serotonin 1B, 2A and 2C receptors in brainstem motoneurons. *Eur J Neurosci* 2003;17:1179–1188.
10. Horner RL. Control of genioglossus muscle by sleep state-dependent neuromodulators. *Adv Exp Med Biol* 2008;605:262–267.
11. Horner RL. Neuromodulation of hypoglossal motoneurons during sleep. *Respir Physiol Neurobiol* 2008;164:179–196.
12. Tryba AK, Peña F, Ramirez JM. Gasping activity in vitro: a rhythm dependent on 5-HT_{2A} receptors. *J Neurosci* 2006;26:2623–2634.
13. Mahamed S, Mitchell GS. Simulated apnoeas induce serotonin-dependent respiratory long-term facilitation in rats. *J Physiol* 2008;586:2171–2181.
14. Eckert DJ, Malhotra A, Jordan AS. Mechanisms of apnea. *Prog Cardiovasc Dis* 2009;51:313–323.
15. Green AR, Mehan AO, Elliott JM, O'Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). *Pharmacol Rev* 2003;55:463–508.
16. Gudelsky GA, Yamamoto BK. Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons. *Pharmacol Biochem Behav* 2008;90:198–207.
17. O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Moliver ME. Methylenedioxymethamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. *J Neurosci* 1988;8:2788–2803.
18. Hatzidimitriou G, McCann UD, Ricaurte GA. Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. *J Neurosci* 1999;19:5096–5107.
19. McCann UD, Szabo Z, Seckin E, et al. Quantitative PET studies of the serotonin transporter in MDMA users and controls using [¹¹C]McN5652 and [¹¹C]DASB. *Neuropsychopharmacology* 2005;30:1741–1750.
20. Semple DM, Ebmeier KP, Glabus MF, O'Carroll RE, Johnstone EC. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ("ecstasy") users. *Br J Psychiatry* 1999;176:63–69.
21. Thomasius R, Zapletalova P, Petersen K, et al. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. *J Psychopharmacol* 2006;20:211–225.
22. McCann UD, Ricaurte GA. Effects of (+/-) 3,4-methylenedioxymethamphetamine (MDMA) on sleep and circadian rhythms. *Sci World J* 2007;7:231–238.
23. Parrott AC. Human research on MDMA (3,4-methylenedioxymethamphetamine) neurotoxicity: cognitive and behavioural indices of change. *Neuropsychobiology* 2000;42:17–24.
24. Zakzanis KK, Campbell Z, Jovanovski D. The neuropsychology of ecstasy (MDMA) use: a quantitative review. *Hum Psychopharmacol* 2007;22:427–435.
25. Kalechstein AD, De La Garza R II, Mahoney JJ III, Fante-grossi WE, Newton TF. MDMA use and neurocognition: a meta-analytic review. *Psychopharmacology* 2007;189:531–537.
26. de Win MM, Jager G, Booij J, et al. Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users. *Brain* 2008;131(pt 11):2936–2945.
27. McCann UD, Ridenour A, Shaham Y, Ricaurte GA. Serotonin neurotoxicity after (+/-) 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy"): a controlled study in humans. *Neuropsychopharmacology* 1994;10:129–138.
28. First MB, Spitzer RL, Gibbon M, Williams JB. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), clinician version. Arlington, VA: American Psychiatric Publishing Inc; 1997.
29. Iber C, Ancoli-Israel S, Chesson AL, Quan SF. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology, and Technical Specifications. Westchester, IL: American Academy of Sleep Medicine; 2007.
30. Morgan MJ, Impallomeni LC, Pirona A, Rogers RD. Elevated impulsivity and impaired decision-making in abstinent

- ecstasy (MDMA) users compared to polydrug and drug-naïve controls. *Neuropsychopharmacology* 2006;31:1562–1573.
31. Quednow BB, Kühn KU, Hoppe C, Westheide J, Maier W, Daum I, Wagner M. Elevated impulsivity and impaired decision-making cognition in heavy users of MDMA (“ecstasy”). *Psychopharmacology* 2007;189:517–530.
32. McCann UD, Eligulashvili V, Mertl M, Murphy DL, Ricaurte GA. Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users. *Psychopharmacology* 1999;147:56–65.
33. Gerra G, Zaimovic A, Ferri M, et al. Long-lasting effects of (+/–)3,4-methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans. *Biol Psychiatry* 2000;47:127–136.
34. Banks S, Dinges DF. Behavioral and physiological consequences of sleep restriction. *J Clin Sleep Med* 2007;3:519–528.
35. Carskadon MA, Acebo C, Jenni OG. Regulation of adolescent sleep: implications for behavior. *Ann NY Acad Sci* 2004;1021:276–291.
36. O’Brien EM, Mindell JA. Sleep and risk-taking behavior in adolescents. *Behav Sleep Med* 2005;3:113–133.
37. Carley DW, Pavlovic S, Janelidze M, Radulovacki M. Functional role for cannabinoids in respiratory stability during sleep. *Sleep* 2002;25:391–398.

More Ways to Meet Your Maintenance of Certification Requirements

New NeuroSAE™ Now Available!

Now you can get additional practice with the new 2008 version of the popular AAN NeuroSAE (Neurology Self-Assessment Examination). The 2007 and 2008 versions of this unique practice test are designed to help you meet the American Board of Psychiatry and Neurology (ABPN) self-assessment requirement for Maintenance of Certification.

- Content outline based on the outline used for the ABPN’s cognitive examination for recertification in clinical neurology
- 100 Multiple-choice questions help you determine strengths and areas for improvement
- Convenient—take online on your own schedule
- Receive feedback by subspecialty area and suggestions for further reading
- Compare your performance to other neurologists
- \$99/examination for AAN members and \$149/examination for nonmembers

Take one—or both—versions. Visit www.aan.com/neurosae today!

Neurology[®]

Sleep apnea in young abstinent recreational MDMA ("ecstasy") consumers

Una D. McCann, Francis P. Sgambati, Alan R. Schwartz, et al.

Neurology 2009;73;2011-2017 Published Online before print December 2, 2009

DOI 10.1212/WNL.0b013e3181c51a62

This information is current as of December 2, 2009

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/73/23/2011.full
Supplementary Material	Supplementary material can be found at: http://n.neurology.org/content/suppl/2009/12/02/WNL.0b013e3181c51a62.DC1 http://n.neurology.org/content/suppl/2009/12/06/WNL.0b013e3181c51a62.DC2
References	This article cites 35 articles, 5 of which you can access for free at: http://n.neurology.org/content/73/23/2011.full#ref-list-1
Citations	This article has been cited by 1 HighWire-hosted articles: http://n.neurology.org/content/73/23/2011.full##otherarticles
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): All Neuropsychology/Behavior http://n.neurology.org/cgi/collection/all_neuropsychology_behavior Other toxicology http://n.neurology.org/cgi/collection/other_toxicology Sleep apnea http://n.neurology.org/cgi/collection/sleep_apnea
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright . All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.